Ovid Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
Mailing Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
Phone
212-776-4381
Fiscal Year End
1231
EIN
465270895
Financial Overview
FY2025
$130.66M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
Annual Reports
10-K
March 18, 2026
- Developing novel therapies for rare neurological diseases with significant unmet medical needs.
- Strategic collaborations are key to funding development and accessing specialized expertise.
Insider Trading
SELL
2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.